CardiolRx
Phase 3Small molecule
CardiolRx is one of 9 small molecule programs targeting Pericarditis. It is currently in Phase 3.
1
Indications
3
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Pericarditis
#DrugCompanyPhaseTrials
1Colcrys
Jazz PharmaceuticalsApproved
Bayer Aspirin
BayerApproved
Epidiolex
Jazz PharmaceuticalsApproved
Kineret
SSwedish Orphan Biovitrum
Phase 3
RPH-104
UUnknown Sponsor
Phase 3
CardiolRx
CCardiol Therapeutics Inc.
Phase 3
KPL-387
KKiniksa Pharmaceuticals International, plc
Phase 2
VTX2735
ZZomagen Biosciences Ltd.
Phase 2
Spikevax
ModernaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CardiolRx. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CCardiol Therapeutics Inc.